Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Opus Genetics, Inc. (IRD)

Opus Genetics presents gene therapy data; 3 of 4 BEST1 participants improved

Positive Impact 3 of 5 other Written later

Opus Genetics presented interim clinical data from its OPGx-BEST1 and OPGx-LCA5 gene therapy trials at Retina in Rio 2026 on October 14, 2026, and furnished the press release and slides in this 8-K. The company said the data are interim and based on small participant groups, and it expects Phase 3 dosing for OPGx-LCA5 to begin in the fourth quarter of 2026.

Key points

  • OPGx-BEST1 low-dose Cohort 1: three of four evaluable participants (75%) showed improved retinal sensitivity in the treated transitional zone.
  • OPGx-LCA5 adults showed sustained improvements in visual acuity and light sensitivity through 24 months; three pediatric participants showed results through six months.
  • OPGx-BEST1 high-dose Cohort 2 has completed enrollment with 11 participants.
  • Phase 3 dosing for OPGx-LCA5 is expected in the fourth quarter of 2026.

The filing

CompanyOpus Genetics, Inc. (IRD)
Form8-K, current report
Filed with the SECOct 15, 2026, 5:23 PM ET
Accession number0001140361-26-039781

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.